ArticlePloS one2016
Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Development and Validation of an Interpretable Machine Learning Model for StagingJournal of medical Internet research · 2026Article
- Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.Breast cancer research and treatment · 2025Article
- Predicting doxorubicin-induced cardiotoxicity in breast cancer: leveraging machine learning with synthetic data.Medical & biological engineering & computing · 2025Article
- Preoperative blood neutrophil-to-lymphocyte ratio, hematocrit and fibrinogen predict prognosis in colorectal cancer.Biomarkers in medicine · 2025Article
- The Importance of Hypoxia-Related to Hemoglobin Concentration in Breast Cancer.Cell biochemistry and biophysics · 2024Review
- β-D-Glucose-Reduced Silver Nanoparticles Remodel the Tumor Microenvironment in a Murine Model of Triple-Negative Breast Cancer.International journal of molecular sciences · 2024Article
- Efficacy of circulating microRNA-130b and blood routine parameters in the early diagnosis of gastric cancer.Oncology letters · 2021Article
- Preoperative low hematocrit is an adverse prognostic biomarker in ovarian cancer.Archives of gynecology and obstetrics · 2021Article
- High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma.OncoTargets and therapy · 2021Article
- The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers.Translational cancer research · 2020Article
- Adverse effects of being underweight on young female breast cancer patients with lymph node metastases.Journal of Cancer · 2020Article
- Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer.PloS one · 2018Article
- Low Hematocrit Is a Strong Predictor of Poor Prognosis in Lung Cancer Patients.BioMed research international · 2018Article
- DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia usually refers to low hemoglobin (Hb) levels. Previous studies indicated that anemia negatively influence the survival in various cancers. Hematocrit (HCT) is the volume percentage of red blood cells in blood, which could indicate anemia in both individuals and populations. This study compared the value of HCT with that of Hb for predicting outcomes of patients who underwent treatment for triple negative breast cancer (TNBC).
methodsA retrospective study of 293 triple negative breast cancer patients, accepting treatment from January 2004 to December 2009 at Sun Yat-sen University Cancer Center, was conducted. Kaplan-Meier curves and multivariate Cox proportional models were used to calculate disease free survival (DFS) and overall survival (OS).
resultsThe cut-off value of HCT was 35.9% determined by X-tile software analysis. The cut-off value of Hb was 12.0 g/dl based on the World Health Organization (WHO) criteria. In univariate analysis, low HCT and low Hb were both significantly associated with decreased DFS and OS. In multivariate analysis, HCT (HR: 0.570; 95% CI: 0.331-0.981, P = 0.042 for DFS; HR: 0.456; 95% CI: 0.256-0.813, P = 0.008 for OS) was still identified as independent predictor of outcome, but not Hb.
conclusionPretreatment low HCT is independently associated with poor prognosis in TNBC patients. However, HCT was found to be superior to Hb in terms of predicting breast cancer mortality. In the future, large-scale prospective studies or validation studies are needed to verify our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.